Shares of NRx Pharmaceuticals, Inc. (NRXP) are down over 32% at $2.40 in premarket trading today, following the release of results from a phase IIb/III trial of NRX-101 in treatment of suicidal bipolar depression.
In the study, NRX-101 demonstrated a 33% reduction in sustained remission in suicidality (not statistically significant at this sample size) and 75% advantage in relief from Akathisia relative to Lurasidone, according to the company.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.